Herzliya, Israel and Calgary, Alberta – (Newsfile Corp. – September 3, 2021) – Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”), is is pleased to announce that the company recently conducted an experimental study of its CBD-laden liposome technology (LPT) in large animals, which demonstrated a similar pharmacokinetic profile to a previous small animal study. The company aims to bring these results closer to human clinical trials.
Pharmacokinetics (PK) determines the course of drug concentrations in the blood as a function of time from the time of administration and thus indicates the effectiveness of the drug.
The prolonged release of cannabidiol (CBD) from the liposomes injected subcutaneously into a large animal showed continuous levels of CBD in the blood over a long period of time. Similar to what was previously found in small animal studies and is considered a good predictor of expected exposure in humans. The data obtained suggest that Innocan’s LPT platform may be suitable for therapeutic applications in humans.
Continuous exposure to CBD in the blood for a long period of time after topical administration appears to be superior to orally administered CBD in two ways: All of this allows for a single dose rather than a daily dose and overcomes the low (10-20%) oral bioavailability of CBD. The superior PK of CBD in LPT can make it possible to achieve a controlled concentration of CBD in the blood, leading to a better clinical outcome.
Figure 1: CEO Iris Bincovich and Prof. Chezy Barenholz at the Laboratory of Membrane and Liposome Research at the Hebrew University of Jerusalem
To view an improved version of this graphic, please visit:
Prof. Chezy Barenholz of the Hebrew University of Jerusalem said, “The preliminary results of prolonged exposure to CBD in a large animal after injection of CBD-laden liposomes will bring us closer to a human clinical trial.” Barenholz added, “Such results serve as a better predictor of the human PK profile. The “leap” from a small animal model to a large animal model is of immense importance for the development of the LPT platform for humans. “
The story goes on
“Innocan is slowly and surely being positioned as the global leader in converting CBD into a treatable pharmaceutical solution because of our scientific breakthroughs and innovations,” said Iris Bincovich, CEO of Innocan Pharma, adding, “We believe the pharmaceutical industry is watching the market as we continue to disrupt this emerging but unsaturated market. “
The company also announces that yesterday it granted a total of 4,150,000 options to directors, officers, employees and service providers under its option plan at an exercise price of $ 0.59 CDA for a term of 5 years.
Innocan’s relationship with the Hebrew University
Innocan Pharma Ltd., a wholly-owned subsidiary of the Company, has an exclusive worldwide research and license agreement with Yissum Research and Development Company (“Yissum”), the commercial arm of the Hebrew University of Jerusalem, for the design, manufacture, characterization and licensing Review of hydrogels containing liposomes loaded with CBD (or other cannabinoids). The research and development initiative is led by Professor Chezy Barenholz, director of the Department of Membrane and Liposome Research at Hebrew University, the inventor of over 55 patent families, two of which are based on Doxil®, an FDA-cleared treatment drug of breast cancer. This unique liposome platform technology can have a wide range of uses such as epilepsy, pain relief, inflammation, and central nervous system disorders. A patent application was filed for this technology on October 7, 2019.
Innocan Pharma is a pharmaceutical technology company focused on developing multiple CBD-containing drug delivery platforms. Tel Aviv University’s Innocan Pharma and Ramot are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 coronavirus using CBD. CBD-laden exosomes have the potential to help restore infected lung cells. This product, which is expected to be given by inhalation, will be tested for various lung infections.
Innocan Pharma has signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled-release liposome for administration by injection. Innocan Israel, together with Professor Barenholz, plans to test the liposome platform under several possible conditions. Innocan Israel is also working on a skin product that integrates CBD with other pharmaceutical ingredients, as well as developing and selling CBD-integrated medicines, including but not limited to topical treatments for the relief of psoriasis symptoms, as well as the treatment of muscle pain and rheumatic diseases Pains. Innocan Israel founders and officers each have successful track records in the pharmaceutical and technology sectors in Israel and around the world.
For more information please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
Lytham Partners, LLC
Ben Shamsian CPA | Vice President
Direct: 646-829-9701; Cell phone: 516-652-9004`Shamsian
NEITHER CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICES HAVE VERIFIED OR TAKE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NOTICE.
Caution with forward-looking information
Certain information contained in this press release including, but not limited to, information regarding research and development, collaborations, the potential to treat disease, and other therapeutic effects arising from research and / or the Company’s products, required regulatory information Approvals and the time of market entry are forward-looking information within the meaning of applicable securities laws. By its very nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this press release is based on certain key expectations and assumptions by Innocan, including expectations and assumptions regarding the expected benefits of the products, the fulfillment of regulatory requirements in various jurisdictions and the satisfactory conclusion of the necessary production and distribution agreements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experiences to differ materially from the expected results or expectations in this press release. The most important risks and uncertainties include, but are not limited to: general global and local (national) economic, market and business conditions; regulatory and regulatory requirements and actions by government agencies; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks inherent in the nature of product distribution, including import / export matters and failure to obtain (or timely) required regulatory and other approvals and the availability of product inputs and finished products on any market products. The anticipated market entry schedule may change for a number of reasons, including the inability to meet required regulatory requirements or the need for additional time to finalize and / or perform the manufacturing and distribution agreements. Based on the foregoing, readers should not place undue reliance on the forward-looking information in this press release as to the timing of product distribution. For a full discussion of other risks affecting Innocan, please also refer to Innocan’s public reports and filings available on Innocan’s profile at www.sedar.com.
Readers are cautioned that they should not place undue reliance on forward-looking information, as actual results could differ materially from those anticipated in the forward-looking information. Innocan undertakes no obligation to update, correct or revise any forward-looking information as a result of new information, future events or otherwise, unless this is required under applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95564